

R James White

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7850755/r-james-white-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

2,466
citations

18
h-index

49
g-index

58
ext. papers

3,067
ext. citations

8.2
avg, IF

4.43
L-index

#	Paper	IF	Citations
51	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension.. <i>Respiratory Medicine</i> , 2022 , 193, 106744	4.6	
50	Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension. <i>Hypertension</i> , 2022 , 79, 79-92	8.5	0
49	Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension.. <i>Respiratory Medicine Case Reports</i> , 2022 , 37, 101646	1.2	
48	Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. <i>ERJ Open Research</i> , 2021 , 7,	3.5	4
47	An untapped resource: characteristics of thrombus recovered from intermediate or high risk pulmonary embolus patients. <i>Cardiovascular Pathology</i> , 2021 , 57, 107392	3.8	0
46	Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS. <i>Hand</i> , 2021 , 1558944721999727	1.4	
45	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 209-221	10.2	30
44	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 573-584	35.1	22
43	Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza. <i>Thrombosis Research</i> , 2021 , 205, 40-43	8.2	0
42	Resting heart rate as a surrogate for improvement in intermediate risk pulmonary embolus patients?. <i>Respiratory Medicine</i> , 2021 , 187, 106578	4.6	
41	Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. <i>Respiratory Medicine</i> , 2021 , 188, 106596	4.6	0
40	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	2
39	Heart rate monitoring improves clinical assessment during 6-min walk. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020972572	2.7	2
38	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1759-1770	9.5	6
37	Liver Backscatter and the Hepatic Vasculature's Autocorrelation Function. <i>Acoustics</i> , 2020 , 2, 3-12	2	4
36	Heart Rate Expenditure Correlates with Right Ventricular Function. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 372-375	4.7	5
35	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 707-717	10.2	40

34	Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020952019	2.7	5
33	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2640-2645	15.4	13
32	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020941491	2.7	1
31	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020973124	2.7	2
30	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , 2019 , 20, 208	7.3	8
29	The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 331-335	5.1	18
28	Combination therapy improves vascular volume in female rats with pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019 , 317, L445-L455	5.8	1
27	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 227-238	35.1	55
26	EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. <i>Pulmonary Circulation</i> , 2019 , 2045894019866335	2.7	
25	Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats. <i>Experimental Lung Research</i> , 2018 , 44, 51-61	2.3	7
24	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 834-842	1.9	17
23	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. <i>Pulmonary Circulation</i> , 2017 , 7, 167-174	2.7	20
22	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 193-201	5.8	38
21	8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain. <i>Pain Medicine</i> , 2017 , 18, 2515-2517	2.7	1
20	Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 1434-6	10.2	9
19	Estrogen: Friend or Foe in Pulmonary Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 1084-6	10.2	7
18	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 894-901	35.1	37
17	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015 , 373, 834-44	59.2	618

16	Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease. <i>PLoS ONE</i> , 2015 , 10, e0127443	3.7	32
15	Thrombosis, platelets, microparticles and PAH: more than a clot. <i>Drug Discovery Today</i> , 2014 , 19, 1230-5	8.8	33
14	A Pharmacokinetic and Tolerability Comparison in Subjects Transitioning From Twice Daily to Three Times Daily Dosing of Oral Treprostinil. <i>Chest</i> , 2014 , 146, 865A	5.3	9
13	Traversing and labeling interconnected vascular tree structures from 3D medical images 2014 ,		3
12	Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. <i>Pulmonary Circulation</i> , 2013 , 3, 611-21	2.7	26
11	Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. <i>Circulation</i> , 2013 , 127, 624-33	16.7	238
10	Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 61, 474-81	3.1	27
9	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2583-93	4	7
8	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 137-49	5.8	141
7	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009 , 297, L706-14	5.8	15
6	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. <i>Liver Transplantation</i> , 2009 , 15, 30-6	4.5	74
5	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , 2009 , 119, 2894-903	16.7	769
4	Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH. <i>Advances in Pulmonary Hypertension</i> , 2009 , 8, 32-36	0.5	2
3	Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 293, L583-90	5.8	99
2	Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. <i>Chest</i> , 2005 , 128, 612S-613S	5.3	11
1	Pulmonary arterial hypertension: building a better mouse trap for 2010. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004 , 1, 351-359		2